Gilead Buys Tubulis to Boost ADC Platform

Gilead Sciences has entered a definitive agreement to acquire Tubulis, a private Germany-based, clinical-stage biotechnology company, for up to $5 billion, which adds a clinical-stage antibody-drug conjugate (ADC) pipeline and a next-generation platform designed to enhance selective payload delivery to Gilead’s portfolio, the company announced on April 7, 2026. In particular, the deal brings Tubulis’ lead asset, TUB-040, a sodium-dependent phosphate transporter (NaPi2b)-targeting ADC currently in phase 1b/2 development for platinum-resistant ovarian cancer and non-small cell lung cancer, into Gilead’s expanding oncology portfolio.¹

The acquisition also includes TUB-030, a 5T4-targeted ADC with early clinical activity across solid tumors, and Tubulis’ proprietary Tubutecan linker-payload technology. These components are designed to improve stability, tumor specificity, and therapeutic index, which represent key limitations that have historically constrained ADC performance.²

This move reflects growing competition in the ADC space, in which platform differentiation, particularly in linker chemistry and payload design, is becoming a central driver of clinical and commercial success.² By integrating Tubulis’ capabilities, Gilead is positioning itself to compete more directly with established and emerging ADC leaders.¹

How do next-generation ADC platforms influence oncology pipelines?

ADCs have re-emerged as one of the fastest-growing modalities in oncology, driven by advances in linker stability and payload potency.³ Tubulis’ platform focuses on generating “uniquely matched” ADCs with optimized biophysical properties, aiming to deliver sustained tumor exposure while minimizing off-target toxicity, according to the company.¹

The Tubutecan payload, a topoisomerase I inhibitor, aligns with a broader industry shift toward this class of cytotoxic agents, which has demonstrated strong efficacy across multiple tumor types.⁴ However, the differentiating factor increasingly lies in how precisely these payloads are delivered, making conjugation technology a key battleground.³

“The agreement to acquire Tubulis is a significant milestone in Gilead’s progress in oncology,” said Daniel O’Day, chairman and CEO, Gilead Sciences, in a company press release.¹ “The company brings a clinical-stage candidate that is a potential new treatment for ovarian cancer, as well as a next-generation ADC platform and a promising early pipeline.”

What does this deal signal about competition in the ADC market?

The transaction underscores a broader wave of investment and consolidation in ADCs, as companies seek to secure proprietary technologies that can unlock best-in-class or first-in-class potential. The deal, which includes a $3.15 billion upfront payment and up to $1.85 billion in milestones, highlights the value being placed on validated platforms with early clinical proof-of-concept.¹

This competitive dynamic is being driven by the growing clinical success of ADCs across solid tumors, as well as the recognition that incremental improvements in targeting and delivery can translate into meaningful gains in efficacy and safety.⁵

“From the outset, we believed our conjugation technology platforms could have broad impact across the ADC field and the initial data from TUB-040 have reinforced that conviction,” said Dominik Schumacher, PhD, CEO and co-founder, Tubulis, in the release.¹ “Through our existing collaboration, Gilead has already seen the potential of our technologies, and, together, we are well positioned to accelerate the development of our ADC pipeline.”

By adding Tubulis’ pipeline and platform, Gilead strengthens its ability to address high unmet need in oncology while expanding its technological foundation for future ADC development. The deal also reinforces the role platform innovation, not just individual assets, play in defining what may be the next phase of oncology drug development.

References

1. Gilead Sciences. Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline. Published April 7, 2026. Accessed April 7, 2026. https://www.gilead.com/news/news-details/2026/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline
2. Zhou X, Han Y, Fang Y, et al. Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy. Med 2025;6(10):100849. doi: 10.1016/j.medj.2025.100849
3. Su D, Zhang D. Linker design impacts antibody-drug conjugate pharmacokinetics and efficacy via modulating the stability and payload release efficiency. Front. Pharmacol. 2021;12:687926. doi: 10.3389/fphar.2021.687926
4. Han S, Lim KS, Blackburn BJ, et al. The potential of topoisomerase inhibitor-based antibody-drug conjugates. Pharmaceutics. 2022;14(8):1707. doi: 10.3390/pharmaceutics14081707
5. Rubahamya B, Dong S, Thurber GM. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data. Sci. Adv. 2024;10:eadk1894. doi:10.1126/sciadv.adk1894